A review of sleep disorders and melatonin.
Study Design
- Тип исследования
- Review
- Вмешательство
- A review of sleep disorders and melatonin.
- Препарат сравнения
- Placebo
- Направление эффекта
- Positive
- Риск систематической ошибки
- Unclear
Abstract
Sleep disorders are a group of conditions that affect the ability to sleep well on a regular basis and cause significant impairments in social and occupational functions. Although currently approved medications are efficacious, they are far from satisfactory. Benzodiazepines, antidepressants, antihistamines and anxiolytics have the potential for dependence and addiction. Moreover, some of these medications can gradually impair cognition. Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone produced by the pineal gland and released exclusively at night. Exogenous melatonin supplementation is well tolerated and has no obvious short- or long-term adverse effects. Melatonin has been shown to synchronize the circadian rhythms, and improve the onset, duration and quality of sleep. It is centrally involved in anti-oxidation, circadian rhythmicity maintenance, sleep regulation and neuronal survival. This narrative review aims to provide a comprehensive overview of various therapeutic functions of melatonin in insomnia, sleep-related breathing disorders, hypersomnolence, circadian rhythm sleep-wake disorders and parasomnias. Melatonin offers an alternative treatment to the currently available pharmaceutical therapies for sleep disorders with significantly less side effects.
Used In Evidence Reviews
Similar Papers
Journal of sleep research · 2017
European guideline for the diagnosis and treatment of insomnia.
Reviews of reproduction · 1998
Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology.
Clinical therapeutics · 2016
Review of Safety and Efficacy of Sleep Medicines in Older Adults.
Nutrients · 2017
Dietary Sources and Bioactivities of Melatonin.
Brain research. Molecular brain research · 2005
Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro.
Diabetes, obesity & metabolism · 2015